Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Minotti

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Seminars in Oncology|December 1, 2019
Helping the cardio-oncologist: from real life to guidelinesSaro H Armenian, Wojciech Jurczak, Joseph R Carver, et al.
Chemical Research in Toxicology|September 17, 2002
Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclinesPierantonio Menna, Emanuela Salvatorelli, Rossella Giampietro, et al.
Biochimica Et Biophysica Acta|January 18, 2015
The concomitant management of cancer therapy and cardiac therapyEmanuela Salvatorelli, Pierantonio Menna, Emilia Cantalupo, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Chemotherapy|March 7, 2021
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real LifePierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, et al.
Biofactors (Oxford, England)|August 5, 2003
Gamma-glutamyltransferase-dependent prooxidant reactions: a factor in multiple processesSilvia Dominici, Aldo Paolicchi, Evelina Lorenzini, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 17, 2012
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicinEmanuela Salvatorelli, Pierantonio Menna, Sekhar Surapaneni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 14, 2012
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosisEmanuela Salvatorelli, Michele De Tursi, Pierantonio Menna, et al.
Chemotherapy|November 21, 2018
Isavuconazole: Case Report and Pharmacokinetic ConsiderationsFrancesco Marchesi, Corrado Girmenia, Bianca Maria Goffredo, et al.
Seminars in Oncology|December 1, 2019
Treatment specific toxicities: Hormones, antihormones, radiation therapyChris Plummer, Richard M Steingart, Wojcech Jurczak, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Seminars in Oncology|December 1, 2019
Helping the cardio-oncologist: from real life to guidelinesSaro H Armenian, Wojciech Jurczak, Joseph R Carver, et al.
Chemical Research in Toxicology|September 17, 2002
Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclinesPierantonio Menna, Emanuela Salvatorelli, Rossella Giampietro, et al.
Biochimica Et Biophysica Acta|January 18, 2015
The concomitant management of cancer therapy and cardiac therapyEmanuela Salvatorelli, Pierantonio Menna, Emilia Cantalupo, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patientsEmanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Chemotherapy|March 7, 2021
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real LifePierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, et al.
Biofactors (Oxford, England)|August 5, 2003
Gamma-glutamyltransferase-dependent prooxidant reactions: a factor in multiple processesSilvia Dominici, Aldo Paolicchi, Evelina Lorenzini, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 17, 2012
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicinEmanuela Salvatorelli, Pierantonio Menna, Sekhar Surapaneni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 14, 2012
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosisEmanuela Salvatorelli, Michele De Tursi, Pierantonio Menna, et al.
Chemotherapy|November 21, 2018
Isavuconazole: Case Report and Pharmacokinetic ConsiderationsFrancesco Marchesi, Corrado Girmenia, Bianca Maria Goffredo, et al.
Seminars in Oncology|December 1, 2019
Treatment specific toxicities: Hormones, antihormones, radiation therapyChris Plummer, Richard M Steingart, Wojcech Jurczak, et al.
Pageof 13